[go: up one dir, main page]

MX2022009280A - Vacunas de arn contra el coronavirus. - Google Patents

Vacunas de arn contra el coronavirus.

Info

Publication number
MX2022009280A
MX2022009280A MX2022009280A MX2022009280A MX2022009280A MX 2022009280 A MX2022009280 A MX 2022009280A MX 2022009280 A MX2022009280 A MX 2022009280A MX 2022009280 A MX2022009280 A MX 2022009280A MX 2022009280 A MX2022009280 A MX 2022009280A
Authority
MX
Mexico
Prior art keywords
rna vaccines
vaccines
coronavirus rna
coronavirus
rna
Prior art date
Application number
MX2022009280A
Other languages
English (en)
Inventor
Guillaume Stewart-Jones
Vladimir Presnyak
Andrea Carfi
Elisabeth Narayanan
Hamilton Bennett
Mihir Metkar
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MX2022009280A publication Critical patent/MX2022009280A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción se refiere a vacunas de ácido ribonucleico (ARN) contra el coronavirus, así como a métodos de uso de las vacunas y composiciones que comprenden las vacunas.
MX2022009280A 2020-01-28 2021-01-26 Vacunas de arn contra el coronavirus. MX2022009280A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062967006P 2020-01-28 2020-01-28
US202062971825P 2020-02-07 2020-02-07
US202063002094P 2020-03-30 2020-03-30
US202063009005P 2020-04-13 2020-04-13
US202063016175P 2020-04-27 2020-04-27
PCT/US2021/015145 WO2021154763A1 (en) 2020-01-28 2021-01-26 Coronavirus rna vaccines

Publications (1)

Publication Number Publication Date
MX2022009280A true MX2022009280A (es) 2022-08-16

Family

ID=74669543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009280A MX2022009280A (es) 2020-01-28 2021-01-26 Vacunas de arn contra el coronavirus.

Country Status (15)

Country Link
US (1) US20230108894A1 (es)
EP (1) EP4096710A1 (es)
JP (1) JP2023511633A (es)
KR (1) KR20220133224A (es)
CN (1) CN115175698A (es)
AU (1) AU2021213108A1 (es)
BR (1) BR112022014837A2 (es)
CA (1) CA3168902A1 (es)
CO (1) CO2022011685A2 (es)
DO (1) DOP2022000152A (es)
IL (1) IL295016A (es)
MX (1) MX2022009280A (es)
PE (1) PE20221756A1 (es)
TW (1) TW202142556A (es)
WO (1) WO2021154763A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) * 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
CN116113430A (zh) 2020-02-04 2023-05-12 奎尔法克股份有限公司 冠状病毒疫苗
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CA3167493A1 (en) * 2020-02-14 2021-08-19 Anne De Groot T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of covid-19
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
EP3901260A1 (en) * 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021159130A2 (en) * 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
WO2022218503A1 (en) * 2021-04-12 2022-10-20 BioNTech SE Lnp compositions comprising rna and methods for preparing, storing and using the same
TW202237148A (zh) * 2020-11-16 2022-10-01 德商拜恩迪克公司 包含rna之lnp組合物以及製備、儲存及使用彼之方法
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CN118109489A (zh) * 2020-12-31 2024-05-31 四川大学华西医院 编码新型冠状病毒的结构蛋白的核酸分子及其疫苗的应用
AU2022208057A1 (en) * 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
CA3208303A1 (en) * 2021-01-15 2022-07-21 Modernatx, Inc. Variant strain-based coronavirus vaccines
JP2024509240A (ja) * 2021-03-08 2024-02-29 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 核酸脂質ナノ粒子の乾燥粉末製剤
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
DK4319803T3 (da) * 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
US20240228549A1 (en) 2021-04-29 2024-07-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
US20240321387A1 (en) 2021-05-04 2024-09-26 BioNTech SE Immunogen selection
CN115594742A (zh) * 2021-07-09 2023-01-13 复旦大学（Cn） 一种冠状病毒s蛋白变体及其应用
EP4419081A1 (en) 2021-10-22 2024-08-28 Sail Biomedicines, Inc. Mrna vaccine composition
WO2023086961A1 (en) 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
KR20240107356A (ko) 2021-11-23 2024-07-09 세일 바이오메디슨스, 인크. 박테리아-유래 지질 조성물 및 이의 용도
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4440613A2 (en) * 2021-11-30 2024-10-09 Novavax, Inc. Coronavirus vaccine formulations
WO2023098842A1 (en) * 2021-12-03 2023-06-08 Suzhou Abogen Biosciences Co., Ltd. NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN
JP2025500373A (ja) 2021-12-20 2025-01-09 セイル バイオメディシンズ インコーポレイテッド Ｍｒｎａ治療用組成物
WO2023121264A1 (ko) * 2021-12-20 2023-06-29 아이진 주식회사 변이 sars-cov-2 백신 조성물 및 이의 용도
US20250099574A1 (en) * 2021-12-22 2025-03-27 Hanmi Pharm Co., Ltd. Coronavirus vaccine
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2023154818A1 (en) * 2022-02-09 2023-08-17 Modernatx, Inc. Mucosal administration methods and formulations
CN114404584B (zh) * 2022-04-01 2022-07-26 康希诺生物股份公司 一种新型冠状病毒mRNA疫苗及其制备方法和用途
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CA3251467A1 (en) 2022-05-05 2023-11-09 Etherna Immunotherapies Nv MULTI-EPITOPE CONSTRUCTION
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US20250228814A1 (en) 2022-06-22 2025-07-17 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024014770A1 (ko) * 2022-07-14 2024-01-18 엠큐렉스 주식회사 mRNA 백신 및 치료제의 제조를 위한 변형된 RNA
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
EP4615424A1 (en) 2022-11-10 2025-09-17 Sail Biomedicines, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
EP4654952A1 (en) 2023-01-27 2025-12-03 Sail Biomedicines, Inc. A modified lipid composition and uses thereof
CN117886903A (zh) * 2023-03-03 2024-04-16 上海蓝鹊生物医药有限公司 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用
WO2024220712A2 (en) * 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024249626A1 (en) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 envelope triple tandem trimers and their use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP1604688B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
RU2524431C2 (ru) 2007-09-26 2014-07-27 Интрексон Корпорейшн Синтетические 5 utr (нетранслируемые области), экспрессионные векторы и способ повышения трансгенной экспрессии
US8785611B2 (en) 2007-12-11 2014-07-22 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
AU2010278309B2 (en) 2009-07-31 2013-10-31 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
JP6561378B2 (ja) 2012-06-08 2019-08-21 トランスレイト バイオ， インコーポレイテッド 非肺標的細胞へのｍＲＮＡの経肺送達
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
SI2970456T1 (sl) 2013-03-14 2022-01-31 Translate Bio, Inc. Postopki in sestavki za dostavo MRNA-kodiranih protiteles
ES2670529T3 (es) 2013-03-15 2018-05-30 Translate Bio, Inc. Mejora sinergística de la entrega de ácidos nucleicos a través de formulaciones mezcladas
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
KR101793271B1 (ko) 2015-07-09 2017-11-20 인텔렉추얼디스커버리 주식회사 공기압을 이용한 휴대용 살균수 스프레이건
HRP20220872T1 (hr) * 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント

Also Published As

Publication number Publication date
PE20221756A1 (es) 2022-11-11
IL295016A (en) 2022-09-01
WO2021154763A1 (en) 2021-08-05
TW202142556A (zh) 2021-11-16
CO2022011685A2 (es) 2022-08-30
JP2023511633A (ja) 2023-03-20
BR112022014837A2 (pt) 2022-09-27
DOP2022000152A (es) 2022-10-31
AU2021213108A1 (en) 2022-08-18
CN115175698A (zh) 2022-10-11
EP4096710A1 (en) 2022-12-07
CA3168902A1 (en) 2021-08-05
US20230108894A1 (en) 2023-04-06
KR20220133224A (ko) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2022009280A (es) Vacunas de arn contra el coronavirus.
WO2023283642A3 (en) Pan-human coronavirus concatemeric vaccines
MX2022009429A (es) Composiciones para la inmunizacion contra virus respiratorios.
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
MX2022009707A (es) Vacunas de dominio de arnm contra el sars-cov-2.
PH12018500855A1 (en) Herpes simplex virus vaccine
EP4349404A3 (en) Respiratory virus vaccines
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
CL2008003596A1 (es) Fitasa enzimaticamente susceptible, polinucleotido que la codifica, casete de expresion, vector y celula huesped que comprenden dicho acido nucleico; metodo de preparacion de la fitasa, y composiciones que la comprenden.
UA93533C2 (en) Insecticidal composition
PH12013502284A1 (en) Protein-active agent conjugates and method for preparing the same
MX2022012561A (es) Composiciones y metodos para silenciar la expresion de la subunidad alfa tipo ix dependiente del voltaje del canal de sodio (scn9a).
WO2024191860A3 (en) Nucleic acid influenza vaccines and respiratory virus combination vaccines
MX2022006748A (es) Composiciones de acidos nucleicos.
WO2021231263A3 (en) Nucleic acid amplification methods
MX2010005094A (es) Complejo de acido nucleico y composicion de suministro de acido nucleico.
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
WO2023114936A3 (en) Subtilisin variants and methods of use
WO2023114932A3 (en) Subtilisin variants and uses thereof
MX2022012493A (es) Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
MX2023014976A (es) Composiciones y metodos para silenciar la expresion de miocilina (myoc).
AR121205A1 (es) Vacunas de arn contra el coronavirus
PH12022552080A1 (en) Compositions and methods for silencing vegf-a expression